The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer.
Hiroya Takiuchi
Consultant or Advisory Role - Taiho Pharmaceutical; Takeda
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Naohiro Tomita
Honoraria - Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Takeda; Yakult Honsha
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Toshiaki Watanabe
Honoraria - Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Takeda; Yakult Honsha
Kenjiro Kotake
Honoraria - Taiho Pharmaceutical
Michio Itabashi
Honoraria - Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Keiichi Takahashi
Honoraria - Taiho Pharmaceutical; Takeda
Hideo Baba
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Satoshi Morita
Consultant or Advisory Role - Taiho Pharmaceutical; Yakult Honsha
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical
Kenichi Sugihara
Consultant or Advisory Role - Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda (I)
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Yakult Honsha; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda